Central monitoring is built for scale, and it works best when data points are structured and easy to compare across a large subject pool. Below 50 subjects, that same design starts to work against the reviewer as volume-driven trend detection needs volume it doesn’t have.
Central monitoring is the right approach for most studies, however low-volume studies need a different approach.
Central monitoring is strongest when data points are comparable at scale. Low-volume studies rarely offer that, and one subject’s lab drift, symptom pattern, or tolerability shift can matter long before it would ever surface in a population view.
That creates three common problems:
In practice, teams spend more time assembling information than interpreting risk. What’s needed in this scenario is the ability to follow a patient’s story as it unfolds, without starting over every time new data comes in.
The missed signals are usually subtle. A mild but persistent LFT drift, a cluster of low-grade symptoms, or a gradual shift in tolerability may look insignificant in isolation.
Viewed over time, those changes can tell a very different story. When reviewers can’t see sequence, context, and comparison together, they’re far more likely to dismiss weak signals or spot them too late: precisely the cases where aggregate trending has the least to offer.
Good oversight in small studies starts with context. Reviewers need one place where the subject story is aligned over time, so they can see what happened, what changed, and what still needs attention.
It also needs visible change. Teams should be able to focus on new, updated, or missing data instead of re-reviewing the same full dataset every cycle.
And it needs comparison. When something looks unusual, reviewers should be able to benchmark that subject against similar cohorts, dose levels, or event patterns quickly.
The better model isn’t less central monitoring, but central monitoring paired with structured subject-level oversight that keeps the patient story intact and makes change easy to see.
Together, that combination helps teams:
It also gives reviewers a more defensible basis for action, which matters when subject numbers are low and each decision carries more weight.
Central monitoring remains a core part of oversight at any scale. But below 50 subjects, it can’t carry the whole job on its own as the most important signals usually appear at the patient level, so oversight has to start there too.
Good oversight isn’t about choosing between the two. It’s about pairing central monitoring with clearer context and smarter comparison at the subject level.